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The absence of pathological hallmarks of progressive multiple sclerosis (MS) in 
commonly used rodent models of experimental autoimmune encephalomyelitis (EAE) 
hinders the development of adequate treatments for progressive disease. Work reviewed 
here shows that such hallmarks are present in the EAE model in marmoset monkeys 
(Callithrix jacchus). The minimal requirement for induction of progressive MS pathology is 
immunization with a synthetic peptide representing residues 34–56 from human myelin 
oligodendrocyte glycoprotein (MOG) formulated with a mineral oil [incomplete Freund’s 
adjuvant (IFA)]. Pathological aspects include demyelination of cortical gray matter with 
microglia activation, oxidative stress, and redistribution of iron. When the peptide is for-
mulated in complete Freund’s adjuvant, which contains mycobacteria that relay strong 
activation signals to myeloid cells, oxidative damage pathways are strongly boosted 
leading to more intensive pathology. The proven absence of immune potentiating danger 
signals in the MOG34–56/IFA formulation implies that a narrow population of antigen- 
experienced T cells present in the monkey’s immune repertoire is activated. This novel 
pathway involves the interplay of lymphocryptovirus-infected B  cells with MHC class 
Ib/Caja-E restricted CD8+ CD56+ cytotoxic T lymphocytes.
Keywords: multiple sclerosis, animal model, demyelination, experimental autoimmune encephalomyelitis, 
epstein–Barr virus, B cell
iNTRODUCTiON
Multiple sclerosis (MS) is a devastating autoimmune neurological disease that damages the human 
central nervous system (CNS) through inflammation and tissue injury (1, 2). With an incidence 
of 1 per 1,000 affected individuals and two million patients worldwide, MS is the most common 
non-traumatic neurological disorder in young adults (3). The pathological hallmark of the disease 
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and the most likely cause of the neurological deficits is the lesion, 
a usually well-defined area where axon-enwrapping myelin 
sheaths are destroyed, a process indicated as demyelination. 
Lesions typically display a variable degree of inflammation, i.e., 
infiltration of lymphocytes and monocytes into meninges and 
CNS parenchyma together with local activation of microglia 
cells, axonal injury, and proliferation of astrocytes (gliosis) (4). 
Depending on the disease stage, lesions can be located in the 
white matter (WM) and gray matter (GM) of brain and spinal 
cord (5, 6).
The disease course observed in the majority of MS 
patients (±70%) can be divided into three phases (7): 1. A pre- 
symptomatic phase without detectable clinical symptoms where 
intra-CNS focal inflammation can be detected on magnetic 
resonance images. 2. A relapsing–remitting (RR) phase where 
episodes of disease activity (relapses) alternate with intermittent 
recovery (remission). A subset of patients displays clinically 
isolated syndrome, a usually short-lasting episode with a single 
neurological deficit (e.g., optic neuritis), as first clinical event. 
3. A secondary progressive (SP) phase where clinical symptoms 
worsen progressively, while remissions become less frequent 
and ultimately disappear. In a minority of patients (±15%), the 
disease course is progressive from the onset; this is primary 
progressive (PP) MS (8). The transition of RR to SPMS cannot 
be accurately determined as there are no clear clinical, imaging, 
or immunological parameters that define the transition point 
(7). One established factor determining the onset of progres-
sive disease is the age of the patient rather than the duration of 
the antecedent RR disease (9). It is also unclear whether SP and 
PPMS are identical or different clinical entities (10).
Accumulating evidence indicates profound differences in 
the underlying pathogenic mechanisms between RRMS and 
SP/PPMS. The pathogenic process in RRMS is dominated by 
immune-driven inflammation and demyelination, which can 
be reasonably well treated with drugs that modulate or suppress 
immune functions (11). However, such treatments are usually 
ineffective in progressive MS, indicating that the transition from 
RRMS to SPMS is associated with a change of the pathogenic 
mechanism. Our limited understanding of the pathogenic 
mechanisms in progressive MS and the lack of (a) relevant 
animal model(s) contribute to the high unmet need of effective 
treatments for progressive disease. Gaining insight into the rate-
limiting steps in progressive MS as a basis of future innovative 
treatments is, therefore, regarded as the greatest challenge for 
the MS research community (12).
MODeLiNG PROGReSSive MS iN 
ANiMALS
Progressive MS is clinically characterized as gradual worsening 
of neurological functions, which in SP disease manifests after 
a relapsing disease course. The pathology of RR and progres-
sive MS shows many differences, which are briefly summarized 
here. For a detailed description, we refer the reader to recent 
reviews (6, 10).
A prominent macroscopic pathological feature of progressive 
disease is the loss of brain volume (atrophy), which is mainly due 
to the degeneration of chronically demyelinated axons. Another 
pathological feature of progressive MS is demyelination of corti-
cal GM. Intriguing data from Lucchinetti et  al. (13) provides 
compelling evidence that cortical GM lesions are not confined 
to progressive MS, but can be found also in the early phase of 
the disease. For the intra- and leukocortical lesions, an important 
difference between early versus late disease is the presence of 
inflammation in early MS lesions, while inflammation activity has 
been cleared in progressive MS. In subpial lesions, located at the 
cortical surface, inflammation is usually restricted to activation 
of microglia, although inflammatory cell infiltrates can be found 
in the adjacent meninges. The activated microglia contribute to 
tissue injury by the production of various reactive oxygen species 
and proteases. The chronic oxidative stress in lesions disturbs the 
redox state in neurons and axons, which leads to mitochon drial 
dysfunction and ultimately neurodegeneration.
The dominant animal model in the preclinical research of 
MS is the mouse experimental autoimmune encephalomyelitis 
(EAE) model. As, by far, the greatest majority of fundamental 
discoveries in neuroimmunology were done in mice, there 
clearly is a relevance of mouse models for our understanding of 
autoimmune mechanisms in MS. There is a plethora of excellent 
reviews on rodent EAE models in which clinical and patho-
logical aspects as well as their relevance for MS are discussed in 
much greater depth than can be discussed here (14–18). 
We like to refer readers with a specific interest in the mouse 
models of MS to these reviews. Usually, primate EAE models 
are not discussed in these reviews, although these models can 
provide useful information about the pathogenesis of MS, which 
cannot be obtained in rodent EAE models (19). The primary 
aim of this publication is, therefore, to fill this knowledge gap, 
with a focus on progressive MS.
Several mouse EAE models have been proposed as being 
relevant for progressive MS. For example, in the myelin oligoden-
drocyte glycoprotein (MOG)-induced EAE model in Biozzi ABH 
mice the disease starts with alternation of relapses with complete 
remission; but after a certain period of time, residual functional 
recovery becomes incomplete. MOG-induced models in B6 
mice or in non-obese diabetic mice have also been proposed as 
model of progressive MS. In the mouse models, loss of functional 
recovery is found associated with failure of immunoregulatory 
mechanisms, including regulatory T cells, and incomplete repair 
of demyelination. However, pathological hallmarks of progres-
sive MS, in particular demyelination of cortical GM, oxidative 
injury, redistribution of iron, and mitochondrial defects, are less 
common in rodent EAE models than in the human disease or are 
even absent (20). There are two rat models that display cerebral 
GM demyelination and are potentially useful for the study of 
cortical GM demyelination. These are MOG-induced EAE mod-
els in Lew.1AR1 and Lew.1W strains (21) and stereotactic injec-
tion of inflammatory cytokines (TNF-α/IFNγ) into the cortex 
of MOG-induced EAE-affected Lew rats (22).
We will discuss here that the mentioned pathological fea-
tures are present in the EAE model in common marmosets, 
a small-bodied New World primate species (Callithrix jacchus), 
and that, in this respect, this model more closely approximates 
the situation in progressive MS than mouse EAE models.
FiGURe 1 | Patterns of demyelination (PLP) and inflammation (MRP14) in a 
marmoset immunized with multiple sclerosis myelin/complete Freund’s 
adjuvant. This archetypical experimental autoimmune encephalomyelitis 
model is characterized by abundant MRP14+ resident (microglia) and 
infiltrated (macrophages) myeloid cells, which are found in multiple dense 
clusters in the white matter and as a band at the rim of subpial demyelinated 
lesions (arrowheads).
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The common marmoset offers a variety of translationally 
relevant models of human disease (23). Particularly relevant for 
diseases caused by (auto)immune-mediated inflammatory pathol-
ogy (AIMID), such as the here discussed neuro-inflammatory 
disease MS, is the evolutionary proximity to humans, which has 
been estimated at ±40 million years (24). This close evolutionary 
distance is reflected by a high degree of genetic and immuno-
logical similarity (25). This, added to the outbred nature of the 
species and the presence of a pathogen-educated immune system, 
creates a unique experimental animal model for translational 
research into the pathogenesis and treatment of MS.
Depending on the mode of immunization, a given marmoset 
EAE model will display key signs of RR or progressive MS 
pathology. We will discuss neuropathological details of the mod-
els as well as the underlying immunopathogenic mechanisms. 
Intriguingly, a core pathogenic process leading to progressive 
MS pathology in marmosets is formed by an unconventional 
pathogenic mechanism that seems to be absent in mouse EAE 
models. This mechanism involves the cross talk of B  cells 
infected with Callithrichine herpesvirus-3 (CalHV3) and CD8+ 
CD56+ effector memory cytotoxic T  cells, which are reactive 
with a cytomegalovirus (CMV) antigen (26). Of note, CalHV3 
is the marmoset representative within the lymphocryptovirus 
(LCV) genus LCV, which also comprises the human-specific 
LCV Epstein–Barr virus (EBV, HHV4), the rhesus macaque 
exponent rhesus lymphocryptovirus and herpesvirus papio 
from baboons (27).
TRANSiTiON FROM RR TO PROGReSSive 
MS; A wORKiNG CONCePT DeRiveD 
FROM MARMOSeT eAe
According to a published theory MS is a two-stage disease, start-
ing with RRMS that eventually leads to SPMS (28). The current 
evidence indicates that RRMS is caused by an autoimmune 
attack directed at the myelin sheaths, while oligodendrocytes 
(ODC) are (initially) spared and remyelination remains possible. 
Progressive MS is thought to be rather caused by age-associated 
degeneration of ODC and neurons, leading to insufficient repair 
and irreversible damage to the nervous system. However, data 
from pathology studies and from recent therapy trials in PPMS, 
such as the ORATORIO trial testing ocrelizumab, a monoclonal 
antibody (mAb) against human CD20, a broadly expressed 
surface marker of B lineage cells, support a role for autoimmune 
mechanisms also in progressive MS (29, 30).
A central message of this review is the observation that dis-
ease development in the marmoset EAE model follows a similar 
two-stage course (19). Data obtained over the past two decades 
provide insight into the disease mechanisms underlying the 
two disease stages. The first documented induction of MS-like 
disease in marmosets was by Massacesi et al. (31). In the original 
protocol, EAE was induced with human myelin, which was 
formulated with complete Freund’s adjuvant (CFA), followed by 
intravenous injection of heat-killed Bordetella pertussis particles. 
CFA consists of a mineral oil, indicated as incomplete Freund’s 
adjuvant (IFA), and heat-killed mycobacteria (M. tuberculosis or 
M. butyricum) for potentiation of innate immune mechanisms 
(32). In our hands, this protocol induced acute and seriously 
destructive EAE (32). Hence, we modified the protocol to 
immu nization with human myelin, which we isolated from the 
brain WM of an MS patient, formulated with CFA (32). A single 
immunization with this formulation elicited a chronic neuro-
logical disease that displayed MS-like pathology in the WM 
and the GM of brain and spinal cord (Figure 1). In subsequent 
experiments, which are briefly summarized here but discussed 
in greater detail in the next paragraphs, this model was further 
refined to elucidate the core pathogenic mechanism(s).
A critical finding has been that autoimmunity against a specific 
albeit quantitatively minor constituent of MOG is dispensable 
for the initiation of EAE with CNS myelin but essential for the 
development of chronic disease (33). To study the key pathogenic 
role of MOG in chronic EAE in further detail, we immunized 
marmosets with a non-glycosylated recombinant protein 
expressed in E. coli, representing residues 1–125 of human MOG 
(rhMOG), which was formulated with CFA [see next paragraph; 
reviewed in Ref. (34)].
The two-stage pathogenic process observed in the rhMOG/
CFA model (35) is graphically presented in Figure 2. The collec-
tive data (reviewed in subsequent paragraphs) indicate that the 
initiation phase of the model involves a combined autoimmune 
attack of pro-inflammatory CD4+ T  cells, antibodies, macro-
phages (Mfs), and complement factors on CNS WM myelin 
(36). Via this pathway, which recapitulates the immunology of 
mouse EAE models, MS-like lesions are induced in the WM. As 
remy elination frequently occurred, we assume that the myelin-
forming ODC are spared.
After a variable period of time, a second immunopathogenic 
mechanism is activated, which is mediated by CD8+ cytotoxic 
T lymphocytes (CTL) (35). In a model based on selective activa-
tion of the CTL, we found demyelination in the white as well 
as the GM of brain and spinal cord in the absence of myelin-
binding antibodies, suggesting that demyelination may have been 
caused by a cytotoxic process that leads to the death of ODC (33).
FiGURe 3 | Patterns of gray matter (GM) demyelination in a monkey 
sensitized against MOG34–56 in incomplete Freund’s adjuvant (IFA).  
(A) Patterns of demyelination (PLP) staining of the right hemisphere of  
a marmoset with IFA myelin oligodendrocyte glycoprotein experimental 
autoimmune encephalomyelitis. Rectangle 1 encloses a subpial lesion 
[enlargement in (B)] while the area in rectangle 2 indicates a leukocortical  
(LC) and intracortical (IC) lesion; an enlargement is shown in (G). (B) PLP 
staining shows the cortex above the corpus callosum. The area indicated  
by secondary progressive (SP) is a demyelinated GM subpial area. The 
rectangle here shows the border of the subpial lesion that is enlarged in  
(C). The arrowhead in this figure points at a meningeal infiltrate. (C) In this 
enlargement, the arrowhead points at a macrophage (Mf) with PLP 
degeneration products. (D) The meningeal infiltrate adjacent to the subpial 
lesion (B) contains a large number of CD3+ T cells. (e) Staining for MRP14 
shows that cells at the border of the subpial lesion have a microglia 
morphology. (F) Staining for TPPP shows the absence of oligodendrocytes 
(ODC) in the subpial lesion. The arrowhead points at a single surviving 
oligodendrocyte. (G) PLP staining shows the LC and IC lesion from the  
areas indexed by the rectangle in (A). (H) Staining for CNPase shows the 
absence of ODC in the center of the IC lesion. The inset shows a PLP+ 
apoptotic oligodendrocyte at the border of the lesion. (i) Staining for MRP14 
shows the presence of Mfs/microglia in the LC and IC lesion. Size bars:  
(A) 2 mm; (B) 250 µm; (C–F) 100 µm; (G) 250 µm; (H,i) 100 µm.
FiGURe 2 | Working concept for the transition of relapsing–remitting  
multiple sclerosis (RRMS) to secondary progressive multiple sclerosis. 
Depicted are two neurons, which send electrical signals (indicated with 
concentric circles) along axons to organs on which they project. The axons 
are enwrapped with protective myelin sheaths, which are produced and 
repaired by oligodendrocytes (ODC). (1) Healthy myelinated axons. (2) In 
RRMS, the myelin sheath, in this case of the right axon, is attacked by 
binding of an antibody, which recruits inflammatory cells, such as the 
depicted macrophage (Mf). The Mf releases myelinotoxic factors that  
cause demyelination. New myelin formation (remyelination) is possible  
as the oligodendrocyte is spared. (3) In progressive multiple sclerosis,  
the myelin-forming oligodendrocyte is killed by cytotoxic T lymphocytes 
(CTL). Conceptually, this leads to permanent loss of myelination.
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It was noticed that marmosets immunized with a synthetic 
peptide derived from rhMOG, representing residues 34–56, 
henceforth indicated as MOG34–56, formulated with the min-
eral oil IFA, elicited clinical EAE in >90% of the monkeys (33). 
The absence of innate stimulatory factors in the peptide–IFA 
formulation indicates that this highly refined model is based on 
the reactivation of antigen-experienced T and or B cells present 
in the healthy marmoset’s immune repertoire. We noticed that 
in the model induced with MOG34–56/IFA, GM lesions were 
found, which are devoid of ODC (Figure  3). However, these 
were usually limited in number and detectable only in a minority 
(±20%) of the monkeys. We assume that the cases that display 
GM lesions represent high responders to the immunization.
Gray matter pathology was substantially more robust and 
present in a higher number of monkeys in the model induced 
with MOG34–56/CFA, indicating that GM pathology in low 
responder marmosets can be amplified by innate immune 
stimulation of myeloid cells by the mycobacteria present in 
CFA. Lesions in this model are characterized by the activation of 
oxidative damage pathways, including the redistribution of iron 
(37). Interestingly, a recent study showed a critical role of CNS 
infiltrating monocytes expressing C-C chemokine receptor 2 
in the formation of cortical GM demyelination in a marmoset 
EAE model induced with rhMOG/CFA (38). It is tempting to 
speculate that the stimulation of these myeloid effector cells 
with mycobacterial antigens in CFA may have amplified GM 
demyelination in the MOG34–56/CFA model. A direct clinical 
correlate of CFA has, thus, far not been identified in MS patients. 
However, previous work shows that a ligand of toll-like receptors 
(TLR) putatively originating from gut microbiota, i.e., pepti-
doglycan (PGN) from Eubacteria, is imported into the CNS by 
infiltrating myeloid cells (39). It was shown that Staphylococcus 
PGN can potentiate the immune response of B6 mice against a 
non-encephalitogenic challenge with MOG35–55/IFA leading 
to severe clinical EAE (40).
In conclusion, our findings in the marmoset EAE model 
support a two-stage model for the immunological events at the 
transition of RR to SPMS. In the initiation phase of the disease, 
WM lesions representing those found in RRMS are formed by 
the combined attack of inflammatory T helper 1 (Th1) cells and 
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anti-MOG antibodies. In the course of the disease, a second 
pathway is activated mediated by CTL that attack ODC, inducing 
lesions in WM and GM, which resemble those found in progres-
sive MS. The extent of demyelination is substantially amplified 
by the concomitant activation of myeloid cells.
UNRAveLiNG THe TwO AUTOiMMUNe 
PATHwAYS
Figure  4 depicts the different pathogenic involvement of 
T and B cells in the two stages of the pathogenic process in the 
rhMOG/CFA-induced marmoset EAE model.
T Cell involvement
The inoculation of rhMOG/CFA in marmosets initially elicits 
the activation of Caja-DRB*W1201-restricted CD4+ Th1 cells 
specific for the epitope MOG24–36. Of note, Caja is the acro-
nym used for the MHC system of marmosets (from C. jacchus). 
The Th1  cells were found to elicit only mild inflammatory 
lesions in the WM (36, 41), but in conjunction with autoanti-
bodies, binding to a conformational epitope located at the api-
cal side of the molecule, large demyelinated lesions resembling 
those in RRMS were formed (42). The crucial pathogenic role 
of the Th1 cells was confirmed by the robust clinical effect of 
ustekinumab, a human IgG1κ mAb directed against the shared 
p40 subunit of human interleukin (IL)-12 and IL-23 (43). These 
factors are produced by myeloid antigen-presenting cells (APC) 
upon stimulation via TLR (44) and skew the differentiation of 
Th0 precursor cells toward pro-inflammatory Th1 and Th17 
functional profiles.
The second autoimmune pathway, for which thus far no 
equivalent process has been found in mouse EAE models, is 
activated after a variable period of time following EAE initiation 
and seems to dictate the EAE progression rate (35). This pro-
gression pathway 2 involves the activation of Caja-E restricted 
CD8+ CD56+ CTL specific for the epitope MOG40–48 which 
have the capacity to kill target cells pulsed with the MOG40– 
48 epitope (45). Of note, a similar type of T cells has been found 
in MS lesions in close proximity of HLA-E+ ODC, indicating 
a cytotoxic process (46). It is tempting to speculate that the 
absence of ODC in GM lesions formed in the MOG34–56/IFA 
model (Figure 3) is due to a similar process, but this needs to be 
formally proven. Treatment with ustekinumab at a late disease 
stage only delayed the onset of clinically evident EAE, indicating 
that Th1/Th17 cells have a less prominent pathogenic role than 
in the initiation phase of the disease (47).
B Cell involvement
Using a fully human mAb against human CD20 (HuMab7D8), 
which is clonally related to the clinically tested mAb ofatumumab 
(48, 49), we observed a profound effect of B cell depletion on 
lesion formation in WM as well as GM in the rhMOG/CFA 
marmoset EAE model (50, 51). Intriguingly, analogous to the 
disappointing clinical effect in RRMS of atacicept, a chimeric 
protein combining the “transmembrane activator and calcium-
modulator and cytophilin ligand interactor” TACI, a receptor of 
the B cell cytokines BlyS (B lymphocyte stimulator) and APRIL 
(a proliferation-inducing ligand), with the Fc tail of human 
IgG (52), we observed that depletion of both cytokines with 
specific mAbs exerted only moderate clinical effects in the EAE 
model (53). The discrepant clinical effect between the two types 
of treatment was associated with different depletion patterns 
of CalHV3 from the lymphoid compartment: the virus was 
effectively depleted in marmosets treated with the anti-CD20 
mAb but not in EAE marmosets treated with mAbs against BlyS 
or APRIL (45). These and other observations [reviewed in Ref. 
(26)] lead to the novel concept that the crucial pathogenic role of 
B cells in the marmoset EAE model may be executed by a small 
subset of virus-infected B cells, which in humans comprises less 
than 0.005% of all B cells (54). Experiments are in progress to 
test whether selective depletion of this subset exerts a sufficient 
beneficial effect on marmoset EAE. We posit here that this 
mechanism may also explain the established, albeit still elusive 
association between EBV infection and MS risk (55).
The crucial role of B cells in the EAE progression pathway was 
further tested in the highly refined MOG34–56/IFA model in 
which the autoaggressive CTL are directly activated in vivo (33). 
Also in this model, B cell depletion with the ofatumumab-related 
anti-CD20 mAb HuMab7D8 exerted a robust effect on the clinical 
and pathological presentation of EAE, indicating that B cells have 
a crucial role in the activation of the T cells that cause progressive 
MS-like pathology and disease (56). As will be explained in follow-
ing paragraphs, B cells acquire this pathogenic capacity through the 
infection by LCV.
In conclusion, the EAE model in marmosets involves a two-
stage pathogenic process that is initiated by pro-inflammatory 
Th1  cells and perpetuated by CTL. B  cells have a dual role in 
the disease, namely in the initiation phase the production of 
autoantibodies that opsonize myelin and activate damage via 
Mfs and complement and in the progression phase presentation 
of antigen to the CTL. This concept aligns with the recently 
published remarkable beneficial effect of ocrelizumab, an anti-
human CD20 IgG1κ mAb, in progressive MS (30).
UNRAveLiNG THe ATYPiCAL MARMOSeT 
eAe MODeL iNDUCeD wiTH  
MOG34–56/iFA
An important aspect of primates as model of AIMID is that 
they are naturally infected with similar viruses and bacteria as 
those implicated in the shaping of the human immune system, 
for example, β- and γ-herpesviruses. The important contribution 
of the environment in the shaping of a human-like immune 
repertoire in laboratory animals was recently emphasized by the 
observation that specific pathogen-free (SPF) mice cohoused 
with pet shop mice, which have a much richer microbial flora 
than SPF-bred laboratory mice, develop a more human-like 
immune system (57). Our research in the well-characterized 
mar moset EAE model suggests that the CTL, which are capable 
of initiating progressive MS-like pathology in marmoset EAE, 
may originate from a pathogen-educated part of the immune 
repertoire (19, 26). This implies that the mechanisms that initiate 
AB
FiGURe 4 | Two-stage immunopathogenesis of experimental autoimmune encephalomyelitis (EAE) in the rhMOG/complete Freund’s adjuvant (CFA)-induced 
marmoset model. (A) The initiation and progression of EAE in rhMOG/CFA sensitized marmosets are driven by distinct T cell subsets. EAE initiation is mediated by 
the activation of MHC class II/Caja-DRB*W1201-restricted T helper 1 (Th1)/Th17 cells specific for the epitope 24–36 (EAE pathway 1). EAE progression is driven by 
MHC class I/Caja-E restricted activation of CD8+ CD56+ cytotoxic T lymphocytes-specific for MOG40–48 (EAE pathway 2). (B) Overview of the involvement of the 
two pathways in the different EAE models.
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and/or perpetuate EAE in marmosets differ fundamentally from 
those driving EAE in SPF-bred mice.
The previously proposed “response-to-injury” (inside-out) 
paradigm for MS (58) was formulated as an alternative for the 
more widely adhered “response-to-infection” (outside-in) concept 
(59). The essential difference between the two concepts is that in 
the latter paradigm an infectious micro-organism is the direct 
trigger of the disease, while in the former paradigm infectious 
agents make the immune system more responsive to self-antigens 
released from idiopathic injury inside the CNS WM, indicated 
as the primary lesion. Primary lesions seem to occur spontane-
ously without a clear endogenous or exogenous trigger. The 
exact nature of such primary lesions is unknown, but they could 
well be the microglia aggregates that are found in the normal 
appearing WM of MS patients. These aggregates appear in the 
literature under different names—such as pre-active lesions (60), 
microglia nodules (60), or newly forming lesions (61)—but may 
actually represent the same pathological entity (62). It is also well 
FiGURe 5 | Clinical and pathological aspects of an atypical marmoset experimental autoimmune encephalomyelitis model induced with MOG34–56/ 
incomplete Freund’s adjuvant (IFA). (A) 10 unrelated marmosets were immunized at 28 days interval (arrows) with MOG34–56/IFA. Depicted is the  
heterogeneous disease development, comprising early and late responders. (B) A representative T2W magnetic resonance images scan of a formalin- 
fixed brain half, showing multiple hyperintense regions in the white matter. The encircled lesion (red) was examined for presence of inflammation [(C): a,b]  
and demyelination [(C): c,d]. (D) Demyelinated lesions in the cortical gray matter. In these lesions, mononuclear cell infiltrates and antibody deposition are  
absent, while prominent activation of microglia is present.
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possible that primary lesions are not caused by a pathological 
event but may rather be due to aging-associated degeneration 
of myelin (63) or to dietary factors associated with a Western 
life-style (64).
Conceptually, antigens released from these primary lesions 
are captured by APC within the cervical and lumbar lymph 
nodes, which, respectively, drain the brain and spinal cord (58). 
The assumption that EAE progression mechanisms are activated 
in CNS draining lymph nodes is supported by observations 
in the MOG EAE model in Biozzi ABH mice (65) but needs 
to be proven for marmoset EAE. Conceptually, the pattern of 
immune responses to injury is determined by the composition 
and activation state of the immune repertoire, which is shaped 
by the interaction of genetic and environmental factors (58). 
Accordingly, the pathogen-educated immune system of healthy 
marmosets comprises autoaggressive CD8+ CD56+ cytotoxic 
T  cells, which can be activated in  vivo by repeated injection 
(between 1 and 4 at 28 days interval) of human MOG-derived 
peptide 34–56 with the mineral oil IFA as adjuvant (33). 
Immune profiling showed absence of myelin-binding antibodies 
in this model and a narrow cellular response, comprising CD4+ 
CD56+ and CD8+ CD56+ T cells specific for the immunizing 
MOG34–56 peptide (33, 66). Figure  5 shows the variable 
clinical response (Figure 5A) and the lesion load in the cerebral 
WM (Figure  5B). At closer histological examination, inflam-
mation and demyelination can be observed in the cerebral WM 
(Figure 5C) and, albeit only in a subset of the monkeys (±20%), 
in the GM (Figure 5D). The observation that the same formula-
tion was completely inactive in MOG EAE susceptible SPF-bred 
mice, such as Biozzi ABH and C57BL/6 (33), indicates that the 
EAE in marmosets had been induced by antigen-experienced 
T cells, which are apparently present in the healthy marmoset’s 
immune system.
A recent study shows that the immune response elicited by 
the immunization with MOG34–56/IFA is qualitatively het-
erogeneous, possibly reflecting genetic differences outside the 
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MHC region between the monkeys (67). We observed only in 
high responder monkeys, which were characterized by a fast 
EAE progression rate, a clinical effect of IL-7 receptor blockade 
with an anti-human CD127 mAb. This is a potentially important 
finding as polymorphisms in the IL-7 receptor promotor region 
are associated with enhanced MS risk (68). Moreover, Bielekova 
et al. reported that IL-7 responsive (CD4+) T cells specific for 
MOG35–55 are enriched in the blood of MS patients compared 
to healthy controls (69).
B-T CROSS TALK iN THe MOG34–56/iFA 
MODeL
The variety of GM lesion types that present in the marmoset EAE 
model (subpial, intracortical, transcortical) (Figure  3) mirrors 
those found in the MS brain. A recently published analysis shows 
that lesions in the WM as well as those in the GM display clear 
signs of oxidative injury, including activation of the NADPH 
oxidase, redistribution of iron, and oxidant damage to lipids and 
DNA (37). The absence of these features in mouse EAE models 
implies an important translational gap with MS (20). This dif-
ference is rather remarkable as it occurs irrespective of the large 
difference in innate immune stimulation between the mouse 
EAE models, involving strong immune potentiation with the 
adjuvants CFA and B. pertussis, and the marmoset model EAE, 
which is induced with a TLR-ligand-free emulsion of a synthetic 
peptide in IFA.
We posit here that the marmoset EAE model fills the gap 
between mouse EAE models and progressive MS. The model can, 
therefore, be used for developing effective treatments for aspects 
of the disease that cannot be treated with current medications, 
such as the primary and SP forms of MS. Intriguingly, the model 
supports a core pathogenic role of LCV-infected B cells in pro-
gressive MS. The question arises why LCV infection is crucial for 
this pathogenic role of B cells.
It is highly intriguing that a sequence of only 23 amino acids 
(GMEVGWYRPPFSRVVHLYRNGKD; underlined is the core 
epitope MOG40–48) formulated with an adjuvant without innate 
stimulatory activity gives sufficient instruction to the marmoset 
immune system for eliciting the pathologically complex MS-like 
autoimmune disease depicted in Figure 3. The observation that 
this formulation is inactive in SPF-bred mice (33) suggests that 
the observed effects in marmosets may be due to their pathogen-
educated immune system.
A recent study shows that two types of messages are relayed 
from LCV-induced B lymphoblastoid cells (BLC) to T  cells, 
namely those involving the tri-molecular complex of MHC class 
I or II molecule—epitope—T cell receptor and those exchanged 
without cognate epitope recognition (70). Signals relayed from 
the BLC that circumvent antigen recognition include linkage 
of CD70, which is strongly upregulated on BLC, with CD27 
on T cells, causing downregulation of the latter on CD4+ and 
CD8+ T cells. Moreover, we observed reduced expression on 
T  cells of CD127, the receptor of IL-7 on T  cells, associated 
with increased expression of CD95 and PD1 (CD279). In this 
context, it is interesting to note that blocking of the IL-7R with 
an anti-human CD127 mAb abrogated fast EAE development 
in the MOG34–56/IFA model (67). The above-described cel-
lular changes induced in LCV-infected B  cells may need to 
be viewed as an immune escape strategy of the virus (71, 72). 
Interestingly, the production of IL-17A, which is the signature 
cytokine of the MOG34–56/IFA induced marmoset EAE model 
(33), completely depended on the presence of MOG34–56 in 
the culture.
The presence of strongly autoaggressive T cells in the immune 
repertoire of healthy monkeys indicates that these either have 
escaped thymic selection or have been induced by antecedent 
exposure of the marmosets to mimicry epitopes expressed by 
an infectious agent. As will be discussed below, these options 
are not necessarily mutually exclusive. In the model induced 
with MOG34–56/IFA, we observed a dominant role of CD8+ 
CD56+ effector memory CTL, which are restricted by the non-
classical Mhc class Ib allele Caja-E and specific for the epitope 
MOG40–48 (YRPPFSRVV) (45). Analysis of serum antibodies 
revealed that specificities binding myelin particles were absent 
(66), indicating that the autoaggressive CTL may be held 
directly responsible for the observed demyelination of WM 
and cortical GM in this model. The MOG40–48 epitope shares 
sequence identity as well as immunological cross-reaction with 
the major capsid protein of CMV, an immunodominant T cell 
antigen in the human population encoded in the UL86 open 
reading frame (73, 74). The restriction of antigen recognition 
by Caja-E, the expression of a natural killer (NK) cell marker 
(CD56), and the cross-reaction with a peptide derived from an 
immunodominant CMV antigen are reminiscent to NK-CTL 
involved in the control of CMV infection in humans (75). As was 
already mentioned, a similar type of T cells, albeit of different 
specificity, has been identified in MS lesions, where they seemed 
to be engaged in a cytotoxic interaction with HLA-E expressing 
ODC (46). Taken together, these observations led us to posit 
that pathology in this model may be caused by autoaggressive 
T cells related to human NK-CTL which cause demyelination by 
cytotoxic killing of ODC.
Regarding the recognition of age as most important risk fac-
tor in progressive MS (9), it is noteworthy that chronic latent 
CMV infection has been held responsible for age-associated 
changes in the human immune system, such as the expansion of 
CD8+ CD28null T cells, which have been implicated in chronic 
autoimmune inflammation and progressive MS development 
(76–79). Note also that a relevant proportion of the surprisingly 
high frequency of human anti-CMV effector memory T  cells 
in the aging human immune repertoire is directed against the 
UL86 antigen of CMV (74).
A CRiTiCAL ROLe OF MeMORY  
B CeLLS iN MS
For many years, the B lymphocyte has been assigned a sub-
dominant role in the pathogenesis of MS, namely as producers of 
autoantibodies that opsonize myelin and mediate demyelination 
via cytotoxic mechanisms involving complement (CDC) or Mfs 
(ADCC). The humble position of the B cell is rather remarkable 
FiGURe 6 | Space-filling model of monomeric myelin oligodendrocyte 
glycoprotein (PDB accession number 1PKO) in molecular surface 
representation, colored according to B-factor (blue, low rms/rigid; red, high 
rms/flexible). The surface-exposed MOG40–48 epitope (YRSPFSRVV) is 
indicated in white/purple. The P43 and F44 residues, which stick out of the 
plane toward the reader, are not resolved in the structure, probably due to 
the high flexibility of this part of the sequence resulting in a diffuse diffraction 
pattern (109), the V48 residue is buried in the interior of the protein and, 
therefore, not visible. The putative LIR-motif (F43SRV47), which is part of the 
40–48 epitope is shown in purple. The surface exposure of this motif enables 
interaction with the LC3 docking molecule of autophagosomes.
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as EBV, a virus that primarily targets B cells, had already been 
mentioned as a possible trigger of MS in an editorial in the 
Lancet of 1976 (80). The observation that depletion of B cells with 
rituximab, a chimeric mAb directed against human CD20, had 
a profound and persistent suppressive effect in RRMS without 
essentially altering circulating antibody levels caused a paradigm 
shift (81). The research following this enigmatic finding shows 
that B  cells have many more key functions in MS than only 
autoantibody production; they also produce cytokines, present 
autoantigen to T  cells, are the primary target of EBV, which 
they transfer into the CNS and (according to some) organize 
the ectopic lymphoid structures found in the MS brain (82–84). 
For a detailed description of the pathogenic role of B  cells in 
the MS pathogenesis, we like to refer the interested reader to 
the many excellent reviews on this subject (16, 49, 85, 86). An 
important final note is that the pathogenic role of B cells in MS 
may be restricted to a subset, such as memory B  cells (16) or 
the EBV-infected subset (26). This implies that therapies could 
be developed that target only the pathogenic subset of B cells, 
thereby sparing the rest of the repertoire.
LCv iNFeCTiON eMPOweRS B CeLLS 
FOR AUTOiMMUNiTY iNDUCTiON
While EAE is experimentally induced by one or more injections 
of antigen/adjuvant emulsion, MS seems to develop spon tane-
ously without a clear environmental trigger. It is, there fore, an 
important question where and how the autoaggres sive NK-CTL 
discussed in the previous paragraph are activated in the MS 
patient.
We proposed that MS starts with an idiopathic primary lesion 
within the CNS, which in individuals prone to develop MS 
elicits an autoimmune process (58). However, work by Cserr and 
others showed that antigens released from injured CNS myelin 
and captured in draining lymph nodes rather elicited Th2-type 
anti-inflammatory than Th1/Th17-type pro-inflammatory 
T cell responses (87). On the other hand, in the context of EAE, 
pathogenic T cell responses against antigens released from CNS 
myelin injury may be enhanced in CNS draining lymph nodes 
(65, 88). This paradox can be understood when post-translational 
modification of myelin antigens in the inflammatory milieu of 
MS lesions and/or the involvement of APC with particular patho-
genic capacities are taken into account. Both possibilities will be 
further discussed below.
Reverse translation analysis of immunotherapies that were 
or were not clinically effective in MS clinical trials pointed to a 
crucial role of CalHV3-infected B cells in the activation of the 
autoaggressive CTL in this model [for review, see Ref. (26)]. 
Regarding the strong, albeit still elusive, association of EBV 
with MS this is a potentially important finding (89). Recent 
work provided insight into the essential role of the virus in 
the pathogenic process. It was found that the infection with 
LCV endows B  cells with the capacity to cross-present the 
proteolysis-sensitive MOG40–48 epitope from the encephalito-
genic MOG34–56 peptide to MHC-E restricted CTL (90). How 
might this work?
According to an immunological dogma, autoreactive T cells 
are eliminated from the immune repertoire by negative selection 
in the thymus (=central tolerance) against tissue restricted anti-
gens expressed in thymic epithelial cells under the control of the 
autoimmune regulator (91) or self-antigens imported by thymus 
infiltrating dendritic cells and B cells (92, 93). Nevertheless, pres-
ence of potentially hazardous autoaggressive T cells in the healthy 
repertoire has been firmly established (94). A plausible albeit 
poorly examined explanation for the escape of certain autoag-
gressive T cell specificities from negative selection in the thymic 
medulla may be that these are specific for protease-sensitive 
epitopes that are cleaved during processing into MHC binding 
peptides (epitopes) by thymic APC; this has been demonstrated 
for myelin basic protein (MBP) (95).
We hypothesized that in healthy individuals, activation of 
these escaped T  cells in the periphery might be prevented by 
destructive processing of these same epitopes in peripheral 
APC. Mutatis mutandis, this would imply that in MS patients 
this peripheral tolerance mechanism might be impaired when 
B  cells are infected with EBV. We obtained evidence that this 
may indeed be the case for the MOG40–48 epitope of the MOG-
specific CTL that drive disease progression in the marmoset 
EAE model discussed here (90). In brief, we found that the virus 
activates two essential mechanisms in B  cells, namely protein 
citrullination and autophagy, via which the peptide is protected 
against fast degradation (90). Of note, citrullination, the conver-
sion of arginine into citrulline (Citr), is a frequently occurring 
post-translational modification of autoantigens in the MS lesion 
(96) that seems to be relevant for chronic EAE development in 
mice (97).
FiGURe 7 | Extrapolation of marmoset experimental autoimmune encephalomyelitis (EAE) pathways 1 and 2 toward multiple sclerosis. The release of myelin 
antigens from a conceptualized “primary lesion” elicits the activation of distinct EAE mechanisms driven by CD4+ and CD8+ T cells (see Figure 2). The activation  
of CD8+ cytotoxic T lymphocytes by myelin oligodendrocyte glycoprotein processed and presented by Epstein–Barr virus-infected B cells induces progressive 
demyelination by the killing of oligodendrocytes (EAE pathway 2). It is proposed that the ensuing excessive release of myelin antigens elicits in genetically prone 
individuals the activation of pro-inflammatory CD4+ T helper 1 (Th1)/Th17 cells which evoke episodic inflammation-based neurological dysfunction (pathway 1).  
The ensuing clinical symptoms are indicated with the red line.
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In their putative role as APC for the autoaggressive CTL, 
the LCV-infected BLC face the complex challenge to present 
the MOG40–48 epitope to the autoaggressive CTL, while at the 
same time they need to suppress expression of viral antigens 
to avoid detection by the host immune system. The latter is 
achieved by prohibiting epitope loading on MHC and surface 
expression of MHC class Ia molecules (98). The solution for 
this paradox might be that MHC-E molecules are used for the 
presentation of self and viral peptides. A similar dichotomous 
role of HLA-E is exploited by the β-herpesvirus CMV, which 
just like EBV achieves immune escape by downregulating MHC 
class Ia molecules (HLA-A, B, C) and simultaneously upregulat-
ing HLA-E to avoid detection and kill by NK cells (99). It was 
found that depending on the peptide present in the cleft, HLA-E 
binds with inhibitory natural killer group (NKG) 2A/CD94 
receptors expressed by NK cells, or permits cytotoxic activity by 
the binding of a dimer consisting of NKG2C and CD94 (100). 
In the case of CMV, binding of the leader peptide of gpUL40 
antigen directs HLA-E binding with NKG2A/CD94 dimers for 
immune evasion (101). On the other hand, the human immune 
repertoire contains HLA-E restricted NK-CTL with which virus 
antigens, including peptides derived from gpUL40, are detected 
for immune protection (102). Using a competition assay with 
a leader peptide of HLA-G, we could demonstrate binding of 
the MOG40–48 epitope to K562 cells expressing Caja-E or HLA-E 
transgenes. In addition, we confirmed cytotoxic activity of anti-
MOG40–48 marmoset T cells toward peptide-pulsed autologous 
EBV-infected marmoset B cells (45).
Studies on the processing of the rhMOG in human B  cells 
showed that the leading protease in endolysosomal degradation 
is cathepsin G (catG) (103), a serine protease involved in antigen 
processing by B cells (104). Remarkably, B cells display significant 
catG activity although expression of catG mRNA could not be 
detected with conventional PCR (105). A similar observation was 
published by Burster et al. (106). As catG cleaves the immuno-
dominant peptide MOG34–51 at the arginine residues on posi-
tions 41 and 46 (Arg41 and Arg46), the MOG40–48 epitope of the 
CTL is destroyed during processing. Intriguingly, citrullination 
of only the Arg46 residue sufficed for protection of the complete 
MOG35–51 peptide against proteolytic degradation, although the 
peptide contains at least five other potential cleavage sites, includ-
ing the Arg41 residue (107). It was shown that modification of the 
Arg46 is crucial for association of the epitope with the autophagy 
pathway, which provides a virus-induced protection mechanism 
for the peptide (103). The importance of citrullination of the 
Arg46 residue may lie in the fact that this residue is located within 
a putative F-LIR motif (FSRV) via which the peptide can interact 
with the LC3 docking molecule of autophagosomes (105).
The molecular modeling of monomeric MOG shows that 
the MOG40–48 epitope is surface-exposed and is readily acces-
sible for by the peptidylarginine deïminases that catalyze the 
conversion of Arg into Citr (Figure  6). The association of the 
MOG35–51 peptide with LC3 in autophagosomes may not only 
protect the pathologically most relevant MOG40–48 epitope 
against proteolytic degradation but may also bring the epitope 
in close contact with MHC-E molecules, which according to a 
recent paper also associate with LC3 (108).
CONCLUDiNG ReMARKS
A final and obviously highly relevant point of discussion is to 
what extent the pathological mechanisms defined in the marmo-
set EAE models can be extrapolated to the pathogenesis of MS. 
In a seminal review, Stys et al. posited the intriguing concept that 
PPMS is the real MS, which is putatively caused by degenerative 
events (110). This would imply that the induction of RRMS is 
a secondary pathogenic event. On the other hand, the recently 
completed ORATORIO trial indicates a pathogenic role of B cells 
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in PPMS (30). Data obtained in the marmoset EAE revealed 
that the two concepts can be merged.
We propose that in MS the MHC-E restricted NK-CTL that 
drive EAE progression via pathway 2 are triggered early in the 
disease by myelin antigens released from an idiopathic primary 
lesion, e.g., a microglia nodule, with a key role of EBV-infected 
B cells in the presentation of released antigen to the CTL. The 
fact that the MHC-E loci in humans and non-human primate are 
essentially invariant may explain why the effect of MHC-E genes 
on MS risk has not emerged in GWAS studies. In line with our 
proposal Zaguia et al. reported presence of CTL, albeit specific 
for another myelin antigen (MBP) in RRMS lesions in close 
proximity of HLA-E expressing ODC, which seem to undergo a 
cytotoxic attack (46). Although the lack of cross-reactive mAbs 
has hampered the full characterization of the autoaggressive 
IL-17+ve CTL that drive the progression pathway in marmoset 
EAE, the available evidence suggests that they may be related to 
or even identical with CD8+ CD161+ CD28− NK-CTL present 
in the human anti-CMV T cell repertoire; a similar T cell type has 
been implicated in MS (111). The activation of the progression 
pathway depends on presentation of the proteolysis-sensitive 
epitopes MOG40–48 by LCV-infected B  cells. As discussed 
elsewhere (76), these vigilant CTL are characterized by reduced 
sensitivity to immune regulation by Treg cells and are insensitive 
to corticosteroids (76). Moreover, being antigen-experienced 
T  cells, they are likely committed to a functional lineage and, 
therefore, refractory to treatments operating at the level of T cell 
activation and differentiation. This notion may explain the failure 
of immunomodulatory treatments in progressive MS.
As one oligodendrocyte forms multiple (up to 50) myelin 
sheaths, it can be envisaged that the death of already one oligo-
dendrocyte evokes the release of a substantial amount of myelin 
antigens. The marmoset EAE model shows that the release of 
MOG can induce the activation of MHC class II restricted pro-
inflammatory CD4+ T cells (112). There is ample evidence in 
the MS literature that certain alleles of the highly polymorphic 
MHC-DR locus are strongly linked to enhanced susceptibility 
for MS. There is also evidence that regulatory mechanisms 
controlling pro-inflammatory CD4+ T  cells are disturbed in 
MS (113). It can, thus, be envisaged that in genetically prone 
individuals, episodic activation of Th1/Th17  cells can occur, 
which elicits exacerbations of neurological dysfunction super-
imposed on an underlying degenerative process, as depicted in 
Figure 7. The marmoset EAE pathway 1 complies with such a 
mechanism for MOG. Importantly, CD4+ T responses in EAE 
pathway 1 are not necessarily restricted to MOG as shown in 
Biozzi mice and marmosets sensitized against MOG-deficient 
myelin (114, 115).
In conclusion, we present here a novel pathogenic mechanism 
that leads to progressive MS pathology. As reviewed elsewhere 
this new mechanism may also provide a mechanistic explanation 
for the elusive association for the association of EBV and MS 
risk. We posit that in the beginning of the disease the progressive 
MS pathology may not have direct clinical consequences as it 
remains below a clinical threshold (Figure 7). However, short-
lasting bursts of inflammation triggered by CD4+ T cells reacting 
against released myelin antigens can cause episodic disturbance 
of neurological functions (relapses). In this concept, the conver-
sion of RR to SP disease can be viewed as the gradual extinction 
of pathway 1 activity and incrementing relevance of pathway 2.
AUTHOR CONTRiBUTiONS
BH wrote the article and is corresponding author. JD wrote 
part of the article. BF wrote parts of the article and provided 
Figure 6. JL had valuable contribution to the underlying con-
cept and performed final editing of the manuscript. JH wrote 
parts of the article and had valuable contribution to the under-
lying concept. JB had valuable contribution to the underlying 
concept; he also provided Figures 1 and 3. YK (senior author) 
wrote parts of the article and had valuable contribution to the 
underlying concept.
ACKNOwLeDGMeNTS
The authors like to thank Mrs. van Hassel for the artwork.
ReFeReNCeS
1. Compston A, Coles A. Multiple sclerosis. Lancet (2002) 359(9313):1221–31. 
doi:10.1016/S0140-6736(02)08220-X 
2. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple 
sclerosis: an overview. Brain Pathol (2007) 17(2):210–8. doi:10.1111/j. 
1750-3639.2007.00064.x 
3. Flachenecker P, Stuke K. National MS registries. J Neurol (2008) 255(Suppl 6): 
102–8. doi:10.1007/s00415-008-6019-5 
4. Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque 
and its pathogenesis. N Engl J Med (2006) 354(9):942–55. doi:10.1056/
NEJMra052130 
5. Bö L, Geurts JJ, Mork SJ, van der Valk P. Grey matter pathology in mul-
tiple sclerosis. Acta Neurol Scand Suppl (2006) 183:48–50. doi:10.1111/j. 
1600-0404.2006.00615.x 
6. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progres-
sive multiple sclerosis. Lancet Neurol (2015) 14(2):183–93. doi:10.1016/
S1474-4422(14)70256-X 
7. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, 
et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. 
Neurology (2014) 83(3):278–86. doi:10.1212/WNL.0000000000000560 
8. Larochelle C, Uphaus T, Prat A, Zipp F. Secondary progression in multiple 
sclerosis: neuronal exhaustion or distinct pathology? Trends Neurosci (2016) 
39(5):325–39. doi:10.1016/j.tins.2016.02.001 
9. Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, et al. Onset 
of progressive phase is an age-dependent clinical milestone in multiple 
sclerosis. Mult Scler (2013) 19(2):188–98. doi:10.1177/1352458512451510 
10. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathol-
ogy and pathogenesis. Nat Rev Neurol (2012) 8(11):647–56. doi:10.1038/
nrneurol.2012.168 
11. Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis – a quiet 
revolution. Nat Rev Neurol (2015) 11(3):134–42. doi:10.1038/nrneurol. 
2015.14 
12. Salvetti M, Landsman D, Schwarz-Lam P, Comi G, Thompson AJ, Fox RJ. 
Progressive MS: from pathophysiology to drug discovery. Mult Scler (2015) 
21(11):1376–84. doi:10.1177/1352458515603802 
12
’t Hart et al. A Progressive MS Model in Marmosets
Frontiers in Immunology | www.frontiersin.org July 2017 | Volume 8 | Article 804
13. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, 
et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl 
J Med (2011) 365(23):2188–97. doi:10.1056/NEJMoa1100648 
14. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy 
of multiple sclerosis via animal models: 70 years of merits and culprits 
in experimental autoimmune encephalomyelitis research. Brain (2006) 
129(Pt 8):1953–71. doi:10.1093/brain/awl075 
15. Wekerle H, Kurschus FC. Animal models of multiple sclerosis. Drug Discov 
Today Dis Models (2006) 3(4):359–67. doi:10.1016/j.ddmod.2006.11.004 
16. Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells 
are major targets for effective immunotherapy in relapsing multiple sclerosis. 
EBioMedicine (2017) 16:41–50. doi:10.1016/j.ebiom.2017.01.042 
17. Simmons SB, Pierson ER, Lee SY, Goverman JM. Modeling the heterogene-
ity of multiple sclerosis in animals. Trends Immunol (2013) 34(8):410–22. 
doi:10.1016/j.it.2013.04.006 
18. Lassmann H, Bradl M. Multiple sclerosis: experimental models and 
reality. Acta Neuropathol (2017) 133(2):223–44. doi:10.1007/s00401-016- 
1631-4 
19. ’t Hart BA, Gran B, Weissert R. EAE: imperfect but useful models of multiple 
sclerosis. Trends Mol Med (2011) 17(3):119–25. doi:10.1016/j.molmed. 
2010.11.006 
20. Schuh C, Wimmer I, Hametner S, Haider L, Van Dam AM, Liblau RS, et al. 
Oxidative tissue injury in multiple sclerosis is only partly reflected in experi-
mental disease models. Acta Neuropathol (2014) 128(2):247–66. doi:10.1007/
s00401-014-1263-5 
21. Storch MK, Bauer J, Linington C, Olsson T, Weissert R, Lassmann H. 
Cortical demyelination can be modeled in specific rat models of auto-
immune encephalomyelitis and is major histocompatability complex (MHC) 
haplotype-related. J Neuropathol Exp Neurol (2006) 65(12):1137–42. 
doi:10.1097/01.jnen.0000248547.13176.9d 
22. Merkler D, Ernsting T, Kerschensteiner M, Bruck W, Stadelmann C. 
A new focal EAE model of cortical demyelination: multiple sclerosis-like 
lesions with rapid resolution of inflammation and extensive remyelination. 
Brain (2006) 129(Pt 8):1972–83. doi:10.1093/brain/awl135 
23. ’t Hart BA, Abbott DH, Nakamura K, Fuchs E. The marmoset monkey: 
a multi-purpose preclinical and translational model of human biology 
and disease. Drug Discov Today (2012) 17(21–22):1160–5. doi:10.1016/j.
drudis.2012.06.009 
24. Perelman P, Johnson WE, Roos C, Seuanez HN, Horvath JE, Moreira MA, 
et  al. A molecular phylogeny of living primates. PLoS Genet (2011) 7(3): 
e1001342. doi:10.1371/journal.pgen.1001342 
25. Bontrop RE, Otting N, Slierendregt BL, Lanchbury JS. Evolution of major 
histocompatibility complex polymorphisms and T-cell receptor diversity 
in primates. Immunol Rev (1995) 143:33–62. doi:10.1111/j.1600-065X.1995.
tb00669.x 
26. ’t Hart BA, Jagessar SA, Haanstra K, Verschoor E, Laman JD, Kap YS. 
The primate EAE model points at EBV-infected B  cells as a preferential 
therapy target in multiple sclerosis. Front Immunol (2013) 4:145. doi:10.3389/
fimmu.2013.00145 
27. Ehlers B, Spiess K, Leendertz F, Peeters M, Boesch C, Gatherer D, et  al. 
Lymphocryptovirus phylogeny and the origins of Epstein-Barr virus. J Gen 
Virol (2010) 91(Pt 3):630–42. doi:10.1099/vir.0.017251-0 
28. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol (2001) 
2(9):762–4. doi:10.1038/ni0901-762 
29. Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, 
et  al. Meningeal inflammation plays a role in the pathology of primary 
progressive multiple sclerosis. Brain (2012) 135(Pt 10):2925–37. doi:10.1093/
brain/aws189 
30. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, 
et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. 
N Engl J Med (2017) 376(3):209–20. doi:10.1056/NEJMoa1606468 
31. Massacesi L, Genain CP, Lee-Parritz D, Letvin NL, Canfield D, Hauser SL. 
Active and passively induced experimental autoimmune encephalomyelitis 
in common marmosets: a new model for multiple sclerosis. Ann Neurol 
(1995) 37(4):519–30. doi:10.1002/ana.410370415 
32. ’t Hart BA, Bauer J, Muller HJ, Melchers B, Nicolay K, Brok H, et  al. 
Histopathological characterization of magnetic resonance imaging- 
detectable brain white matter lesions in a primate model of multiple sclerosis: 
a correlative study in the experimental autoimmune encephalomyelitis 
model in common marmosets (Callithrix jacchus). Am J Pathol (1998) 
153(2):649–63. 
33. Jagessar SA, Kap YS, Heijmans N, van Driel N, van Straalen L, Bajramovic JJ, 
et  al. Induction of progressive demyelinating autoimmune encephalomy-
elitis in common marmoset monkeys using MOG34-56 peptide in incom-
plete Freund adjuvant. J Neuropathol Exp Neurol (2010) 69(4):372–85. 
doi:10.1097/NEN.0b013e3181d5d053 
34. ’t Hart BA, van Kooyk Y, Geurts JJ, Gran B. The primate autoimmune 
encephalomyelitis model; a bridge between mouse and man. Ann Clin 
Transl Neurol (2015) 2(5):581–93. doi:10.1002/acn3.194 
35. Kap YS, Smith P, Jagessar SA, Remarque E, Blezer E, Strijkers GJ, et  al.  
Fast progression of recombinant human myelin/oligodendrocyte glyco-
protein (MOG)-induced experimental autoimmune encephalomyelitis in 
marmosets is associated with the activation of MOG34-56-specific cytotoxic 
T cells. J Immunol (2008) 180(3):1326–37. doi:10.4049/jimmunol.180.3.1326 
36. Brok HP, Uccelli A, Kerlero De Rosbo N, Bontrop RE, Roccatagliata L, 
de Groot NG, et al. Myelin/oligodendrocyte glycoprotein-induced autoim-
mune encephalomyelitis in common marmosets: the encephalitogenic T cell 
epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. 
J Immunol (2000) 165(2):1093–101. doi:10.4049/jimmunol.165.2.1093 
37. Dunham JD, Bauer J, Campbell GR, Mahad DJ, van Driel N, van der Pol SMA, 
et al. Oxidative injury and iron redistribution are pathological hallmarks of 
marmoset experimental autoimmune encephalomyelitis. J Neuropathol Exp 
Neurol (2017) 76(6):467–78. doi:10.1093/jnen/nlx034 
38. Lagumersindez-Denis N, Wrzos C, Mack M, Winkler A, van der Meer F, 
Reinert MC, et al. Differential contribution of immune effector mechanisms 
to cortical demyelination in multiple sclerosis. Acta Neuropathol (2017) 
134(1):15–34. doi:10.1007/s00401-017-1706-x 
39. Schrijver IA, van Meurs M, Melief MJ, Wim Ang C, Buljevac D, Ravid R, 
et al. Bacterial peptidoglycan and immune reactivity in the central nervous 
system in multiple sclerosis. Brain (2001) 124(Pt 8):1544–54. doi:10.1093/
brain/124.8.1544 
40. Visser L, Jan de Heer H, Boven LA, van Riel D, van Meurs M, Melief MJ, 
et al. Proinflammatory bacterial peptidoglycan as a cofactor for the devel-
opment of central nervous system autoimmune disease. J Immunol (2005) 
174(2):808–16. doi:10.4049/jimmunol.174.2.808 
41. Villoslada P, Abel K, Heald N, Goertsches R, Hauser SL, Genain CP. 
Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin 
oligodendrocyte glycoprotein in naive outbred primates. Eur J Immunol 
(2001) 31(10):2942–50. doi:10.1002/1521-4141(2001010)31:10<2942:: 
AID-IMMU2942>3.0.CO;2-M 
42. von Budingen HC, Hauser SL, Fuhrmann A, Nabavi CB, Lee JI, Genain CP. 
Molecular characterization of antibody specificities against myelin/ 
oligodendrocyte glycoprotein in autoimmune demyelination. Proc Natl 
Acad Sci U S A (2002) 99(12):8207–12. doi:10.1073/pnas.122092499 
43. Brok HP, Van Meurs M, Blezer E, Schantz A, Peritt D, Treacy G, et  al. 
Prevention of experimental autoimmune encephalomyelitis in common 
marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol (2002) 
169(11):6554–63. doi:10.4049/jimmunol.169.11.6554 
44. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: 
related but functionally distinct regulators of inflammation. Annu Rev 
Immunol (2007) 25:221–42. doi:10.1146/annurev.immunol.22.012703.104758 
45. Jagessar SA, Heijmans N, Blezer EL, Bauer J, Blokhuis JH, Wubben JA, 
et al. Unravelling the T-cell-mediated autoimmune attack on CNS myelin in 
a new primate EAE model induced with MOG34-56 peptide in incomplete 
adjuvant. Eur J Immunol (2012) 42(1):217–27. doi:10.1002/eji.201141863 
46. Zaguia F, Saikali P, Ludwin S, Newcombe J, Beauseigle D, McCrea E, 
et al. Cytotoxic NKG2C+ CD4 T cells target oligodendrocytes in multiple 
sclerosis. J Immunol (2013) 190(6):2510–8. doi:10.4049/jimmunol.1202725 
47. ’t Hart BA, Brok HP, Remarque E, Benson J, Treacy G, Amor S, et  al. 
Suppression of ongoing disease in a nonhuman primate model of multiple 
sclerosis by a human-anti-human IL-12p40 antibody. J Immunol (2005) 
175(7):4761–8. doi:10.4049/jimmunol.175.7.4761 
48. Bleeker WK, Munk ME, Mackus WJ, van den Brakel JH, Pluyter M, 
Glennie MJ, et  al. Estimation of dose requirements for sustained in  vivo 
activity of a therapeutic human anti-CD20 antibody. Br J Haematol (2008) 
140(3):303–12. doi:10.1111/j.1365-2141.2007.06916.x 
49. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 anti-
bodies. Clin Immunol (2012) 142(1):31–7. doi:10.1016/j.clim.2011.04.005 
13
’t Hart et al. A Progressive MS Model in Marmosets
Frontiers in Immunology | www.frontiersin.org July 2017 | Volume 8 | Article 804
50. Kap YS, van Driel N, Blezer E, Parren PW, Bleeker WK, Laman JD, et  al.  
Late B cell depletion with a human anti-human CD20 IgG1kappa monoclo-
nal antibody halts the development of experimental autoimmune encepha-
lomyelitis in marmosets. J Immunol (2010) 185(7):3990–4003. doi:10.4049/
jimmunol.1001393 
51. Kap YS, Bauer J, Driel NV, Bleeker WK, Parren PW, Kooi EJ, et  al. B-cell 
depletion attenuates white and gray matter pathology in marmoset exper-
imental autoimmune encephalomyelitis. J Neuropathol Exp Neurol (2011) 
70(11):992–1005. doi:10.1097/NEN.0b013e318234d421 
52. Kappos L, Hartung HP, Freedman MS, Boyko A, Radu EW, Mikol DD, 
et  al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo- 
controlled, double-blind, phase 2 trial. Lancet Neurol (2014) 13(4):353–63. 
doi:10.1016/S1474-4422(14)70028-6 
53. Jagessar SA, Heijmans N, Bauer J, Blezer EL, Laman JD, Migone TS, 
et al. Antibodies against human BLyS and APRIL attenuate EAE development 
in marmoset monkeys. J Neuroimmune Pharmacol (2012) 7(3):557–70. 
doi:10.1007/s11481-012-9384-x 
54. Khan G, Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. 
Is EBV persistence in vivo a model for B cell homeostasis? Immunity (1996) 
5(2):173–9. doi:10.1016/S1074-7613(00)80493-8 
55. Ascherio A, Munger KL, Lunemann JD. The initiation and prevention 
of multiple sclerosis. Nat Rev Neurol (2012) 8(11):602–12. doi:10.1038/
nrneurol.2012.198 
56. Jagessar SA, Heijmans N, Bauer J, Blezer EL, Laman JD, Hellings N, 
et  al. B-cell depletion abrogates T  cell-mediated demyelination in an 
antibody-nondependent common marmoset experimental autoimmune 
encephalomyelitis model. J Neuropathol Exp Neurol (2012) 71(8):716–28. 
doi:10.1097/NEN.0b013e3182622691 
57. Beura LK, Hamilton SE, Bi K, Schenkel JM, Odumade OA, Casey KA, 
et  al. Normalizing the environment recapitulates adult human immune 
traits in laboratory mice. Nature (2016) 532(7600):512–6. doi:10.1038/ 
nature17655 
58. ’t Hart BA, Hintzen RQ, Laman JD. Multiple sclerosis – a response-to- 
damage model. Trends Mol Med (2009) 15(6):235–44. doi:10.1016/j.molmed. 
2009.04.001 
59. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol (2005) 
4(3):195–202. doi:10.1016/S1474-4422(05)01017-3 
60. van der Valk P, Amor S. Preactive lesions in multiple sclerosis. Curr Opin 
Neurol (2009) 22(3):207–13. doi:10.1097/WCO.0b013e32832b4c76 
61. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: 
pathology of the newly forming lesion. Ann Neurol (2004) 55(4):458–68. 
doi:10.1002/ana.20016 
62. Sato F, Martinez NE, Stewart EC, Omura S, Alexander JS, Tsunoda I. 
“Microglial nodules” and “newly forming lesions” may be a Janus face of early 
MS lesions; implications from virus-induced demyelination, the inside-out 
model. BMC Neurol (2015) 15:219. doi:10.1186/s12883-015-0478-y 
63. Bartzokis G. Age-related myelin breakdown: a developmental model of 
cognitive decline and Alzheimer’s disease. Neurobiol Aging (2004) 25(1): 
5–18; author reply 49–62. doi:10.1016/j.neurobiolaging.2003.03.001 
64. ’t Hart BA. Why does multiple sclerosis only affect human primates? Mult 
Scler (2016) 22(4):559–63. doi:10.1177/1352458515591862 
65. van Zwam M, Huizinga R, Heijmans N, van Meurs M, Wierenga-Wolf AF, 
Melief MJ, et  al. Surgical excision of CNS-draining lymph nodes reduces 
relapse severity in chronic-relapsing experimental autoimmune encephalo-
myelitis. J Pathol (2009) 217(4):543–51. doi:10.1002/path.2476 
66. Jagessar SA, Heijmans N, Blezer EL, Bauer J, Weissert R, ’t Hart BA. Immune 
profile of an atypical EAE model in marmoset monkeys immunized with 
recombinant human myelin oligodendrocyte glycoprotein in incomplete 
Freund’s adjuvant. J Neuroinflammation (2015) 12:169. doi:10.1186/s12974- 
015-0378-5 
67. Dunham J, Lee LF, van Driel N, Laman JD, Ni I, Zhai W, et al. Blockade of 
CD127 exerts a dichotomous clinical effect in marmoset experimental auto-
immune encephalomyelitis. J Neuroimmune Pharmacol (2016) 11(1):73–83. 
doi:10.1007/s11481-015-9629-6 
68. Tavakolpour S. Interleukin 7 receptor polymorphisms and the risk of 
multiple sclerosis: a meta-analysis. Mult Scler Relat Disord (2016) 8:66–73. 
doi:10.1016/j.msard.2016.05.001 
69. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. 
Expansion and functional relevance of high-avidity myelin-specific CD4+ 
T cells in multiple sclerosis. J Immunol (2004) 172(6):3893–904. doi:10.4049/
jimmunol.172.6.3893 
70. Dunham J, van Driel N, Eggen BJ, Paul C, ’t Hart BA, Laman JD, et  al. 
Analysis of the cross-talk between EBV-infected B cells and autoaggressive 
T cells in the marmoset EAE model. Clin Transl Immunol (2017)6(2):e127. 
doi:10.1038/cti.2017.1
71. Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint 
blockade in B-cell lymphomas. Nat Rev Clin Oncol (2016) 14(4):203–20. 
doi:10.1038/nrclinonc.2016.168 
72. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, et al. 
Identification of CD70-mediated apoptosis of immune effector cells as a 
novel immune escape pathway of human glioblastoma. Cancer Res (2002) 
62(9):2592–9. 
73. Brok HP, Boven L, van Meurs M, Kerlero de Rosbo N, Celebi-Paul L, 
Kap YS, et al. The human CMV-UL86 peptide 981-1003 shares a crossreactive 
T-cell epitope with the encephalitogenic MOG peptide 34-56, but lacks 
the capacity to induce EAE in rhesus monkeys. J Neuroimmunol (2007) 
182(1–2):135–52. doi:10.1016/j.jneuroim.2006.10.010 
74. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, 
et  al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ 
T  cells dominate the memory compartments of exposed subjects. J Exp 
Med (2005) 202(5):673–85. doi:10.1084/jem.20050882 
75. Moretta L, Romagnani C, Pietra G, Moretta A, Mingari MC. NK-CTLs, 
a novel HLA-E-restricted T-cell subset. Trends Immunol (2003) 24(3):136–43. 
doi:10.1016/S1471-4906(03)00031-0 
76. ’t Hart BA, Chalan P, Koopman G, Boots AM. Chronic autoimmune- 
mediated inflammation: a senescent immune response to injury. Drug 
Discov Today (2013) 18(7–8):372–9. doi:10.1016/j.drudis.2012.11.010 
77. Broux B, Markovic-Plese S, Stinissen P, Hellings N. Pathogenic features 
of CD4+CD28− T  cells in immune disorders. Trends Mol Med (2012) 
18(8):446–53. doi:10.1016/j.molmed.2012.06.003 
78. Vanheusden M, Stinissen P, ’t Hart BA, Hellings N. Cytomegalovirus: a cul-
prit or protector in multiple sclerosis? Trends Mol Med (2015) 21(1):16–23. 
doi:10.1016/j.molmed.2014.11.002 
79. Vanheusden M, Broux B, Welten SP, Peeters LM, Panagioti E, Van Wijmeersch B, 
et al. Cytomegalovirus infection exacerbates autoimmune mediated neuro-
inflammation. Sci Rep (2017) 7(1):663. doi:10.1038/s41598-017-00645-3 
80. Editorial. Editorial: a milestone in multiple sclerosis. Lancet (1976) 1 
(7957):459–60. 
81. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell 
depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl 
J Med (2008) 358(7):676–88. doi:10.1056/NEJMoa0706383 
82. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic 
autoimmune diseases. Trends Immunol (2003) 24(11):584–8. doi:10.1016/j. 
it.2003.09.005 
83. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, 
et  al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis 
brain. J Exp Med (2007) 204(12):2899–912. doi:10.1084/jem.20071030 
84. von Budingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, 
Zamvil SS. Update on the autoimmune pathology of multiple sclerosis: 
B-cells as disease-drivers and therapeutic targets. Eur Neurol (2015) 73 
(3–4):238–46. doi:10.1159/000377675 
85. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B  cells and antibodies in 
multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 
8(11):613–23. doi:10.1038/nrneurol.2012.203 
86. Kinzel S, Weber MS. B cell-directed therapeutics in multiple sclerosis: ratio-
nale and clinical evidence. CNS Drugs (2016) 30(12):1137–48. doi:10.1007/
s40263-016-0396-6 
87. Harling-Berg CJ, Park TJ, Knopf PM. Role of the cervical lymphatics in the 
Th2-type hierarchy of CNS immune regulation. J Neuroimmunol (1999) 
101(2):111–27. doi:10.1016/S0165-5728(99)00130-7 
88. Phillips MJ, Weller RO, Kida S, Iannotti F. Focal brain damage enhances 
experimental allergic encephalomyelitis in brain and spinal cord. Neuro pathol 
Appl Neurobiol (1995) 21(3):189–200. doi:10.1111/j.1365-2990.1995.tb01050.x 
89. Ascherio A, Munger KL. EBV and autoimmunity. Curr Top Microbiol 
Immunol (2015) 390(Pt 1):365–85. doi:10.1007/978-3-319-22822-8_15 
90. ’t Hart BA, Kap YS, Morandi E, Laman JD, Gran B. EBV infection 
and multiple sclerosis: lessons from a marmoset model. Trends Mol Med 
(2016) 22(12):1012–24. doi:10.1016/j.molmed.2016.10.007 
14
’t Hart et al. A Progressive MS Model in Marmosets
Frontiers in Immunology | www.frontiersin.org July 2017 | Volume 8 | Article 804
91. Peterson P, Org T, Rebane A. Transcriptional regulation by AIRE: molecular 
mechanisms of central tolerance. Nat Rev Immunol (2008) 8(12):948–57. 
doi:10.1038/nri2450 
92. Derbinski J, Kyewski B. How thymic antigen presenting cells sample the 
body’s self-antigens. Curr Opin Immunol (2010) 22(5):592–600. doi:10.1016/j.
coi.2010.08.003 
93. Akirav EM, Xu Y, Ruddle NH. Resident B cells regulate thymic expression 
of myelin oligodendrocyte glycoprotein. J Neuroimmunol (2011) 235(1–2): 
33–9. doi:10.1016/j.jneuroim.2011.03.013 
94. Wekerle H. Myelin specific, autoaggressive T  cell clones in the normal 
immune repertoire: their nature and their regulation. Int Rev Immunol (1992) 
9(3):231–41. doi:10.3109/08830189209061793 
95. Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, 
et al. Destructive processing by asparagine endopeptidase limits presentation 
of a dominant T  cell epitope in MBP. Nat Immunol (2002) 3(2):169–74. 
doi:10.1038/ni754 
96. Chirivi RGS, van Rosmalen JWG, Jenniskens GJ, Pruijn GJ, Raats JMH. 
Citrullination: a target for disease intervention in multiple sclerosis and other 
inflammatory diseases? J Clin Cell Immunol (2013) 4(3):146–53. doi:10.4172/ 
2155-9899.1000146 
97. Carrillo-Vico A, Leech MD, Anderton SM. Contribution of myelin autoan-
tigen citrullination to T cell autoaggression in the central nervous system. 
J Immunol (2010) 184(6):2839–46. doi:10.4049/jimmunol.0903639 
98. Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, et  al.  
Epstein-Barr virus evasion of CD8(+) and CD4(+) T  cell immunity via 
concerted actions of multiple gene products. Semin Cancer Biol (2008) 
18(6):397–408. doi:10.1016/j.semcancer.2008.10.008 
99. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, et al. 
Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by 
human cytomegalovirus gpUL40. Science (2000) 287(5455):1031. doi:10.1126/ 
science.287.5455.1031 
100. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL. 
Kinetics and peptide dependency of the binding of the inhibitory NK recep-
tor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. 
EMBO J (1999) 18(15):4250–60. doi:10.1093/emboj/18.15.4250 
101. Braud VM, Tomasec P, Wilkinson GW. Viral evasion of natural killer cells 
during human cytomegalovirus infection. Curr Top Microbiol Immunol 
(2002) 269:117–29. 
102. Pietra G, Romagnani C, Mazzarino P, Falco M, Millo E, Moretta A, 
et  al. HLA-E-restricted recognition of cytomegalovirus-derived peptides 
by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A (2003) 
100(19):10896–901. doi:10.1073/pnas.1834449100 
103. Morandi E, Jagessar SA, ’t Hart BA, Gran B. EBV infection empowers human 
B cells for autoimmunity: role of autophagy and relevance to mul tiple sclero-
sis. J Immunol (2017) ji1700178. doi:10.4049/jimmunol.1700178 
104. Burster T, Beck A, Tolosa E, Marin-Esteban V, Rotzschke O, Falk K, et al. 
Cathepsin G, and not the asparagine-specific endoprotease, controls the 
processing of myelin basic protein in lysosomes from human B lymphocytes. 
J Immunol (2004) 172(9):5495–503. doi:10.4049/jimmunol.172.9.5495 
105. Jagessar SA, Holtman IR, Hofman S, Morandi E, Heijmans N, Laman JD, 
et  al. Lymphocryptovirus infection of nonhuman primate B cells converts 
destructive into productive processing of the pathogenic CD8 T cell epitope 
in myelin oligodendrocyte glycoprotein. J Immunol (2016) 197(4):1074–88. 
doi:10.4049/jimmunol.1600124 
106. Burster T, Macmillan H, Hou T, Boehm BO, Mellins ED. Cathepsin G: roles 
in antigen presentation and beyond. Mol Immunol (2010) 47(4):658–65. 
doi:10.1016/j.molimm.2009.10.003 
107. Raymond WW, Trivedi NN, Makarova A, Ray M, Craik CS, Caughey GH. 
How immune peptidases change specificity: cathepsin G gained tryptic 
function but lost efficiency during primate evolution. J Immunol (2010) 
185(9):5360–8. doi:10.4049/jimmunol.1002292 
108. Camilli G, Cassotta A, Battella S, Palmieri G, Santoni A, Paladini F, et  al. 
Regulation and trafficking of the HLA-E molecules during monocyte- 
macrophage differentiation. J Leukoc Biol (2016) 99(1):121–30. doi:10.1189/
jlb.1A0415-172R 
109. Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, 
et  al. Structural insights into the antigenicity of myelin oligodendrocyte 
glycoprotein. Proc Natl Acad Sci U S A (2003) 100(16):9446–51. doi:10.1073/
pnas.1133443100 
110. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple 
sclerosis please stand up? Nat Rev Neurosci (2012) 13(7):507–14. doi:10.1038/
nrn3275 
111. Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, Cannoni S, 
et  al. CD161(high)CD8+T  cells bear pathogenetic potential in multiple 
sclerosis. Brain (2011) 134(Pt 2):542–54. doi:10.1093/brain/awq354 
112. ’t Hart BA, Kap YS. An essential role of virus-infected B cells in the marmoset 
experimental autoimmune encephalomyelitis model. Mult Scler J Exp Transl 
Clin (2017) 3(1):2055217317690184. doi:10.1177/2055217317690184
113. Venken K, Hellings N, Liblau R, Stinissen P. Disturbed regulatory T  cell 
homeostasis in multiple sclerosis. Trends Mol Med (2010) 16(2):58–68. 
doi:10.1016/j.molmed.2009.12.003 
114. Smith PA, Heijmans N, Ouwerling B, Breij EC, Evans N, van Noort JM, 
et al. Native myelin oligodendrocyte glycoprotein promotes severe chronic 
neurological disease and demyelination in Biozzi ABH mice. Eur J Immunol 
(2005) 35(4):1311–9. doi:10.1002/eji.200425842 
115. Jagessar SA, Smith PA, Blezer E, Delarasse C, Pham-Dinh D, Laman JD, 
et  al. Autoimmunity against myelin oligodendrocyte glycoprotein is dis-
pensable for the initiation although essential for the progression of chronic 
encephalomyelitis in common marmosets. J Neuropathol Exp Neurol (2008) 
67(4):326–40. doi:10.1097/NEN.0b013e31816a6851 
Conflict of Interest Statement: The authors declare that the research was conducted 
in the absence of any commercial or financial relationships that could be construed 
as a potential conflict of interest.
Copyright © 2017 ’t Hart, Dunham, Faber, Laman, van Horssen, Bauer and Kap. 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums is 
permitted, provided the original author(s) or licensor are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. No 
use, distribution or reproduction is permitted which does not comply with these terms.
